Calcium ion coordinated dexamethasone supramolecular hydrogel as therapeutic alternative for control of non-infectious uveitis
Source abstract
Abstract
Supramolecular hydrogels formed by the self-assembly of therapeutic agents have received considerable attention due to their high drug payload and carrier-free features. Herein, we constructed a dexamethasone sodium phosphate (Dex) supramolecular hydrogel in combination with Dex and calcium ion (Ca2+) and further demonstrated its therapeutic efficacy in the control of ocular inflammation. The developed supramolecular hydrogel was thoroughly characterized by rheology, TEM, FTIR and XRD. Calcium ions and Dex concentration had a marked influence on the sol-gel transition behaviour of hydrogel and the proposed Dex supramolecular hydrogel displayed thixotropic properties. The drug release rate from Dex supramolecular hydrogel was dependent on the Ca2+ concentration. In comparison with Dex aqueous solution, single intravitreal injections of Dex supramolecular hydrogel up to 30μg/eye were well tolerated without causing undesirable complications of fundus blood vessel tortuosity and lens opacity, as indicated by electroretinograms (ERGs), fundus photography and histopathology. Moreover, the administration by Dex supramolecular hydrogel exhibited a comparable anti-inflammatory efficacy to native Dex solution on an experimental autoimmune uveitis (EAU) model induced in Lewis rats with IRBP peptide and the therapeutic efficacy had in a dosage-dependent manner. Histological observation and cytokines measurements indicated that both Dex solution and Dex supramolecular hydrogel (30μg/eye) treatment could significantly attenuate the inflammatory response in both anterior and posterior chambers via the downregulation of Th1 and Th17 effector responses. All these data suggested that the developed Dex supramolecular hydrogel might be a therapeutic alternative for non-infectious uveitis with minimal risk of the induction of lens opacity and fundus blood vessel tortuosity. Statement of significance A facile ionic cross-linking strategy was exploited to construct a dexamethasone sodium phosphate (Dex) supramolecular hydrogel composed of Dex and calcium ion. Intravitreal injection of Dex hydrogel displayed excellent intraocular biocompatibility without causing the complications of fundus blood vessel tortuosity and lens opacity. More importantly, the proposed Dex hydrogel exhibited a comparative anti-inflammatory response to native Dex formulation on an experimental autoimmune uveitis (EAU) model via the downregulation of Th1 and Th17 effector responses.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Ocular Diseases and Behçet’s Syndrome · Corneal Surgery and Treatments · Retinal Diseases and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (73)
Show source-provided references
1. Non infectious intermediate and posterior uveitis: treatment and place of local steroids10.1016/j.clinthera.2013.07.340 ↗
2. Immunopharmacotherapy of non-infectious uveitis: where do we stand?10.1517/14712598.2014.963049 ↗
3. Cytokines in autoimmune uveitis10.1089/jir.2011.0042 ↗
4. Corticosteroid-induced glaucoma: a review of the literature10.1038/sj.eye.6701895 ↗
5. Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel10.1016/j.actbio.2015.05.005 ↗
6. Sustained-release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery10.1016/j.jcrs.2015.11.005 ↗
7. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation10.1111/jphp.12224 ↗
8. Periocular corticosteroid injections in uveitis: effects and complications10.1016/j.ophtha.2014.05.021 ↗
9. Recent advances in ocular drug delivery10.3109/03639045.2012.736515 ↗
10. Self-assembly of short peptides to form hydrogels: design of building blocks, physical properties and technological applications10.1016/j.actbio.2013.08.013 ↗
11. Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response10.1016/j.biomaterials.2012.06.003 ↗
12. Molecular hydrogels of hydrophobic compounds: a novel self-delivery system for anti-cancer drugs10.1039/C2SM06923G ↗
13. Rational design of a tetrameric protein to enhance interactions between self-assembled fibers gives molecular hydrogels10.1002/ange.201108612 ↗
14. Installing logic-gate responses to a variety of biological substances in supramolecular hydrogel – enzyme hybrids10.1038/nchem.1937 ↗
15. A supramolecular hydrogel based on carbamazepine10.1039/C5CC05503B ↗
16. Enzyme-instructed intracellular molecular self-assembly to boost activity of cisplatin against drug-resistant ovarian cancer cells10.1002/ange.201507157 ↗
17. Mixing biomimetic heterodimers of nucleopeptides to generate biocompatible and biostable supramolecular hydrogels10.1002/anie.201412448 ↗
18. Nanoscale assemblies of small molecules control the fate of cells10.1016/j.nantod.2015.09.001 ↗
19. Self-assembling hydrogel scaffolds for photocatalytic hydrogen production10.1038/nchem.2075 ↗
20. Molecular hydrogel-stabilized enzyme with facilitated electron transfer for determination of H2O2 released from live cells10.1021/ac500231e ↗
21. Ultrashort cationic naphthalene-derived self-assembled peptides as antimicrobial nanomaterials10.1021/bm500981y ↗
22. Adjustable nanofibers self-assembled from an irregular conformational peptide amphiphile10.1039/C4PY01237B ↗
23. Self-delivery of a peptide-based prodrug for tumor-targeting therapy10.1007/s12274-015-0945-1 ↗
24. Complementary hydrogen bonding interaction triggered co-assembly of an amphiphilic peptide and an anti-tumor drug10.1039/C5CC00501A ↗
25. Rational design and application of responsive α-helical peptide hydrogels10.1038/nmat2479 ↗
26. The importance of the self-assembly process to control mechanical properties of low molecular weight hydrogels10.1039/c3cs60030k ↗
27. Chemically programmed self-sorting of gelator networks10.1038/ncomms2499 ↗
28. Rational design of a tetrameric protein to enhance interactions between self-assembled fibers gives molecular hydrogels10.1002/ange.201108612 ↗
29. Recent advances in steroidal supramolecular gels10.1039/c2ra01343f ↗
30. In situ formation of steroidal supramolecular gels designed for drug release10.3390/molecules18043745 ↗
31. Sodium deoxycholate hydrogels: effects of modifications on gelation, drug release, and nanotemplating10.1021/acs.jpcb.5b00411 ↗
32. In situ clicking methylglyoxal for hierarchical self-assembly of nanotubes in supramolecular hydrogel10.1039/C5NR07179H ↗
33. Low molecular mass cationic gelators derived from deoxycholic acid: remarkable gelation of aqueous solvents10.1016/j.tet.2007.03.118 ↗
34. Supramolecular chemistry of bile acid derivatives: formation of gels10.1002/masy.200650909 ↗
35. Hydrogels as reaction vessels: acenaphthylene dimerization in hydrogels derived from bile acid analogues10.3390/12092181 ↗
36. Conjugation of two complementary anti-cancer drugs confers molecular hydrogels as a co-delivery system10.1039/C1CC16250K ↗
37. Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy10.1039/C4NR04761C ↗
38. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord10.1016/j.biomaterials.2005.11.015 ↗
39. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye10.1016/j.jconrel.2015.01.001 ↗
40. Animal models of autoimmune and immune-mediated uveitis
41. Human S-antigen: presence of multiple immunogenic and immunopathogenic sites in the Lewis rat10.1006/jaut.1993.1048 ↗
42. Intermolecular forces in the self-assembly of peptide amphiphile nanofibers10.1002/adfm.200500161 ↗
43. Tunable mechanics of peptide nanofiber gels10.1021/la9030969 ↗
44. Engineering of an environmentally responsive beta roll peptide for use as a calcium-dependent cross-linking domain for peptide hydrogel formation10.1021/bm3002446 ↗
45. Supramolecular hydrogel exhibiting four basic logic gate functions to fine-tune substance release10.1021/ja8098239 ↗
46. A supramolecular shear-shinning anti-inflammatory steroid hydrogel
47. Calcium ions to cross-link supramolecular nanofibers to tune the elasticity of hydrogels over orders of magnitude10.1021/la2033862 ↗
48. New synthesis route of hydrogel through a bioinspired supramolecular approach: gelation, binding interaction, and in vitro dressing10.1021/acsami.5b05360 ↗
49. Inner ear delivery of dexamethasone using injectable silk-polyethylene glycol (PEG) hydrogel10.1016/j.ijpharm.2016.02.048 ↗
50. Development of chemically cross-linked hydrophilic-hydrophobic hydrogels for drug delivery applications10.1016/j.eurpolymj.2015.10.033 ↗
51. Nanonization strategies for poorly water-soluble drugs10.1016/j.drudis.2010.02.009 ↗
52. Molecular hydrogels of therapeutic agents10.1039/b806410p ↗
53. Recent advances in steroidal supramolecular gels10.1039/c2ra01343f ↗
54. Short-peptide-based molecular hydrogels: novel gelation strategies and applications for tissue engineering and drug delivery10.1039/c2nr31149f ↗
55. Toward complex matter: supramolecular chemistry and self-organization10.1073/pnas.072065599 ↗
56. Elastic behavior of cross-linked and bundled actin networks10.1126/science.1095087 ↗
57. Self-assembled supramolecular nanotube yarn10.1002/adma.201302345 ↗
58. Self-assembling small molecules for the detection of important analytes10.1039/C4CS00161C ↗
59. Supramolecular nanostructures formed by anticancer drug assembly10.1021/ja3115983 ↗
60. Dexamethasone phosphate-loaded folate-conjugated polymeric nanoparticles for selective delivery to activated macrophages and suppression of inflammatory responses10.1007/s13233-015-3065-6 ↗
61. Preparation of ordered porous NaCl and KCl crystals10.1016/j.solidstatesciences.2005.12.012 ↗
62. Conjugation of two complementary anti-cancer drugs confers molecular hydrogels as a co-delivery system10.1039/C1CC16250K ↗
63. Intraocular pressure-dependent retinal vascular change in adult chronic open-angle glaucoma patients10.1016/S0161-6420(91)32187-0 ↗
64. Effect of changes in intraocular pressure on the retinal microcirculation10.1136/bjo.58.5.514 ↗
65. Evaluation of the effect of elevated intraocular pressure and reduced ocular perfusion pressure on retinal capillary bed filling and total retinal blood flow in rats by OMAG/OCT10.1016/j.mvr.2015.07.001 ↗
66. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation10.1016/j.jconrel.2013.01.007 ↗
67. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection10.1001/archopht.1992.01080140115038 ↗
68. Synthesis and characterization of poly (2-hydroxyethylmethacrylate) contact lenses containing chitosan nanoparticles as an ocular delivery system for dexamethasone sodium phosphate10.1007/s11095-016-1903-7 ↗
69. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept10.3109/03639045.2015.1137306 ↗
70. Factors affecting therapeutic decisions in intermediate and posterior uveitis10.1016/j.ajo.2014.10.015 ↗
71. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features
72. Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-γ in Vogt-Koyanagi-Harada patients10.1136/bjo.2008.142489 ↗
73. Differential roles for IFN-γ and IL-17 in experimental autoimmune uveoretinitis10.1093/intimm/dxm135 ↗